US Pharma MarketingThe post Dexcom tweaks full-year outlook after reporting 13% growth in Q2 appeared first on Medical Device Network.
Dexcom tweaks full-year outlook after reporting 13% growth in Q2
Following the release of its Q2 results on 30 July, Dexcom's company’s shares on the Nasdaq rose over 8% to $81.04 at market open on 31 July. The post Dexcom tweaks full-year outlook after reporting 13% growth in Q2 appeared first on Medical Device Network .
Following the release of its Q2 results on 30 July, Dexcom's company’s shares on the Nasdaq rose over 8% to $81.04 at market open on 31 July.
Source: Medical Device Network